MEI Pharma, an oncology company focused on the clinical development of novel therapies for cancer, has appointed Nick Glover, Ph.D., to its board of directors, increasing the board to seven members, including six independent directors.

"In addition to firsthand experience leading an emerging hematology drug development company, Nick has an extensive background in business development and strong relationships within the life science investment community,” said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. “We look forward to the benefit of his experience as we execute multiple phase II clinical trials of Pracinostat in the months ahead and formulate strategies for maximizing its value."

Glover served as president and chief executive officer of YM BioSciences from November 2010 until the completion of its acquisition by Gilead in February 2013. Glover also was president and chief executive officer of Viventia Biotech, involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, and previously he was an investment manager at MDS Capital, a life sciences venture capital firm.